543 related articles for article (PubMed ID: 8477199)
21. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
22. The WHO classification of the myelodysplastic syndromes.
Bain B
Exp Oncol; 2004 Sep; 26(3):166-9. PubMed ID: 15494682
[TBL] [Abstract][Full Text] [Related]
23. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
24. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
Muramatsu H; Makishima H; Maciejewski JP
Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
[TBL] [Abstract][Full Text] [Related]
25. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
26. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Kantarjian HM; Shtalrid M; Kurzrock R; Blick M; Dalton WT; LeMaistre A; Stass SA; McCredie KB; Gutterman J; Freireich EJ
Am J Med; 1988 Nov; 85(5):639-44. PubMed ID: 3189367
[TBL] [Abstract][Full Text] [Related]
27. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders.
Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067
[TBL] [Abstract][Full Text] [Related]
28. Mixed myeloproliferative and myelodysplastic disorders.
Emanuel PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):9-12. PubMed ID: 20425383
[TBL] [Abstract][Full Text] [Related]
29. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?
Oscier DG
Br J Haematol; 1996 Mar; 92(3):582-6. PubMed ID: 8616021
[TBL] [Abstract][Full Text] [Related]
30. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
31. The monocytic component in myelodysplastic syndromes.
Castoldi G; Rigolin GM
Cancer Treat Res; 2001; 108():81-92. PubMed ID: 11702607
[No Abstract] [Full Text] [Related]
32. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
33. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
35. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
37. Chronic myelomonocytic leukemia: Forefront of the field in 2015.
Benton CB; Nazha A; Pemmaraju N; Garcia-Manero G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):222-42. PubMed ID: 25869097
[TBL] [Abstract][Full Text] [Related]
38. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
39. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; D'Elia GM; Alimena G
Leuk Lymphoma; 2008 Jul; 49(7):1292-6. PubMed ID: 18604717
[TBL] [Abstract][Full Text] [Related]
40. Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Tefferi A
Leuk Lymphoma; 2008 Jul; 49(7):1225-7. PubMed ID: 18604709
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]